Literature DB >> 11564366

Osteoporosis.

R Cimaz1, M Biggioggero.   

Abstract

Bone mass is determined primarily by genetic influences, but exogenous factors may also play a major role. The prevention of osteoporosis can start at childhood. Optimal achievement of peak bone mass during childhood and adolescence is important to minimize future fracture risk. Chronic inflammatory diseases can have a detrimental effect on bone mass through a variety of mechanisms. Different diagnostic methods for detecting osteoporosis (eg, dual x-ray absorptiometry, quantitative computed tomography, ultrasounds) are in use or under investigation. New treatment options are available; among these, the use of bisphosphonates seems to be the more promising approach.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564366     DOI: 10.1007/s11926-996-0005-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  39 in total

Review 1.  The genetics of osteoporosis.

Authors:  S H Ralston
Journal:  Bone       Date:  1999-07       Impact factor: 4.398

Review 2.  Expanding role of bisphosphonate therapy in children.

Authors:  L R Shoemaker
Journal:  J Pediatr       Date:  1999-03       Impact factor: 4.406

Review 3.  Bisphosphonates: from grandparents to grandchildren.

Authors:  T Srivastava; U S Alon
Journal:  Clin Pediatr (Phila)       Date:  1999-12       Impact factor: 1.168

4.  Intravenous pamidronate in juvenile osteoporosis.

Authors:  N J Shaw; C M Boivin; N J Crabtree
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

5.  Comparison of quantitative calcaneal ultrasound and dual energy X-ray absorptiometry in the evaluation of osteoporotic risk in children with chronic rheumatic diseases.

Authors:  F Falcini; G Bindi; M Ermini; F Galluzzi; G Poggi; S Rossi; L Masi; R Cimaz; M L Brandi
Journal:  Calcif Tissue Int       Date:  2000-07       Impact factor: 4.333

6.  Evaluation by dual X-ray absorptiometry (DXA) of bone mineral density in children with juvenile chronic arthritis.

Authors:  R M Pereira; J E Corrente; W H Chahade; N H Yoshinari
Journal:  Clin Exp Rheumatol       Date:  1998 Jul-Aug       Impact factor: 4.473

7.  Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.

Authors:  F Falcini; S Trapani; M Ermini; M L Brandi
Journal:  Calcif Tissue Int       Date:  1996-03       Impact factor: 4.333

8.  Estimation of bone mineral density in children with juvenile rheumatoid arthritis.

Authors:  R Hopp; J Degan; J C Gallagher; J T Cassidy
Journal:  J Rheumatol       Date:  1991-08       Impact factor: 4.666

9.  Bone turnover is reduced in children with juvenile rheumatoid arthritis.

Authors:  F Falcini; M Ermini; F Bagnoli
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

10.  Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy.

Authors:  B D Warady; C B Lindsley; F G Robinson; B P Lukert
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.